Clinical Trial Results: A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of three dose concentrations of an RSV vaccine in infants and toddlers; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Immunisation
• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: RSV Immunisation, Healthy Volunteers | Phase 3 | Status: TERMINATED | Results posted: 2026-08-03